Lantern Pharma Inc. Shares Latest Financials and Business Insights

In a recent update, Lantern Pharma Inc., a clinical-stage biopharmaceutical company, has unveiled its financial results for the fourth quarter and the full year of 2024. Known for its innovative approach to drug development, Lantern Pharma leverages artificial intelligence, machine learning, and genomic data to enhance the drug development process and identify patients who are most likely to benefit from its targeted oncology therapies.

The company, which operates in the United States and is listed on the Nasdaq stock exchange, has experienced significant stock price fluctuations over the past year. Its stock reached a 52-week high of $6.7958 USD on May 23, 2024, showcasing investor optimism at the time. However, the stock price later dipped to a 52-week low of $2.55 USD on April 7, 2025, reflecting the volatile nature of the biopharmaceutical sector.

As of the last close on May 8, 2025, Lantern Pharma’s stock price was $3.86 USD. The company’s market capitalization stands at $39,040,000 USD. Despite the challenges reflected in its financial metrics, such as a price-to-earnings ratio of -1.83, Lantern Pharma continues to focus on its core mission of optimizing drug development through cutting-edge technology.

Lantern Pharma’s strategic use of AI and machine learning in oncology drug development positions it uniquely in the healthcare sector. By targeting therapies to specific patient groups, the company aims to improve treatment outcomes and efficiency in the healthcare system.

For investors and stakeholders, Lantern Pharma’s recent financial disclosures provide a snapshot of its current market position and future potential. As the company navigates the complexities of the biopharmaceutical landscape, its commitment to innovation and patient-centric therapies remains a cornerstone of its business strategy.

For more detailed information and updates, Lantern Pharma Inc. can be accessed through its official website at www.lanternpharma.com .